RB-190

RB-190 is a repurposed form of metyrosine, developed by Right Brain Bio as a novel therapy for Parkinson's disease. Unlike current treatments that primarily provide symptomatic relief, RB-190 aims to modify the progression of Parkinson's disease by targeting its root cause. The drug is based on research indicating that excessive dopamine exposure leads to neurotoxicity in Parkinson’s disease. By reducing dopamine synthesis, RB-190 seeks to reverse or halt the underlying pathology rather than just alleviating symptoms. Preclinical studies in multiple models have demonstrated its potential to reverse disease pathology. Metyrosine (the active ingredient) is already FDA-approved for treating complications of pheochromocytoma but is being repurposed here specifically for neurodegenerative application[1][4][6][7].

Other names

metyrosine